Epigenetics enters the stage in vascular malformations
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci182904 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Salim Abdelilah-Seyfried. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Histone Deacetylase 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cerebral arteriovenous malformations represent the most common form of vascular malformations and can cause recurrent bleeding and hemorrhagic stroke. The current issue of the JCI features an article by Zhao et al. describing a mouse model of cerebral arteriovenous malformations. Endothelial cells lacking matrix Gla protein, a BMP inhibitor, underwent epigenetic changes characteristic of an endothelial-to-mesenchymal fate transition. The authors uncovered a two-step process for this transition controlled by the epigenetic regulator histone deacetylase 2 (HDAC2), which controls endothelial cell differentiation, and by enhancer of zeste homolog 1 (EZH1), which suppressed mesenchymal fate. This discovery provides a promising entry point for preventive pharmacological interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Abdelilah-Seyfried, S. (2024). Epigenetics enters the stage in vascular malformations. Journal of Clinical Investigation. https://doi.org/10.1172/jci182904
Vancouver
Abdelilah-Seyfried S. Epigenetics enters the stage in vascular malformations. Journal of Clinical Investigation. 2024. doi:10.1172/jci182904
BibTeX
@article{AbdelilahSeyfried2024,
author = {Abdelilah-Seyfried, Salim},
title = {Epigenetics enters the stage in vascular malformations},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci182904}
}
EUVIMED